1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 4 1.2 List of Figures 8 2 Introduction 9 2.1 Optic Nerve Disorders Report Coverage 9 2.2 Optic Neuropathy - Overview 9 2.3 Glaucoma - Overview 9 2.4 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Overview 9 2.5 Optic Neuritis - Overview 9 3 Therapeutics Development 10 3.1 Optic Neuropathy 10 3.2 Glaucoma 13 3.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 24 3.4 Optic Neuritis 28 4 Therapeutics Assessment 31 4.1 Optic Neuropathy 31 4.2 Glaucoma 37 4.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 47 4.4 Optic Neuritis 52 5 Companies Involved in Therapeutics Development 58 5.1 Optic Neuropathy 58 5.2 Glaucoma 60 5.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 91 5.4 Optic Neuritis 97 6 Dormant Projects 101 6.1 Optic Neuropathy 101 6.2 Glaucoma 102 6.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 106 6.4 Optic Neuritis 107 7 Discontinued Products 108 7.1 Optic Neuropathy 108 7.2 Glaucoma 108 7.3 Optic Neuritis 110 8 Product Development Milestones 111 8.1 Optic Neuropathy 111 8.2 Glaucoma 117 8.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 128 8.4 Optic Neuritis 143 9 Appendix 146 9.1 Methodology 146 9.2 Coverage 146 9.3 Secondary Research 146 9.4 Primary Research 146 9.5 Expert Panel Validation 146 9.6 Contact Us 147 9.7 Disclaimer 147

1.1 List of Tables Table 1: Number of Products under Development for Optic Neuropathy 10 Table 2: Number of Products under Development by Companies, Optic Neuropathy 11 Table 3: Number of Products under Development by Universities/Institutes, Optic Neuropathy 12 Table 4: Products under Development by Companies, Optic Neuropathy 12 Table 5: Products under Development by Universities/Institutes, Optic Neuropathy 13 Table 6: Number of Products under Development for Glaucoma 13 Table 7: Number of Products under Development by Companies, Glaucoma 14 Table 8: Number of Products under Development by Universities/Institutes, Glaucoma 17 Table 9: Products under Development by Companies, Glaucoma 18 Table 10: Products under Development by Universities/Institutes, Glaucoma 23 Table 11: Number of Products under Development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 24 Table 12: Number of Products under Development by Companies, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 25 Table 13: Number of Products under Development by Universities/Institutes, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 26 Table 14: Products under Development by Companies, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 26 Table 15: Products under Development by Universities/Institutes, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 27 Table 16: Number of Products under Development for Optic Neuritis 28 Table 17: Number of Products under Development by Companies, Optic Neuritis 29 Table 18: Number of Products under Development by Universities/Institutes, Optic Neuritis 30 Table 19: Products under Development by Companies, Optic Neuritis 30 Table 20: Products under Development by Universities/Institutes, Optic Neuritis 30 Table 21: Number of Products by Stage and Target, Optic Neuropathy 32 Table 22: Number of Products by Stage and Mechanism of Action, Optic Neuropathy 33 Table 23: Number of Products by Stage and Route of Administration, Optic Neuropathy 35 Table 24: Number of Products by Stage and Molecule Type, Optic Neuropathy 36 Table 25: Number of Products by Stage and Target, Glaucoma 38 Table 26: Number of Products by Stage and Mechanism of Action, Glaucoma 41 Table 27: Number of Products by Stage and Route of Administration, Glaucoma 45 Table 28: Number of Products by Stage and Molecule Type, Glaucoma 47 Table 29: Number of Products by Stage and Target, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 48 Table 30: Number of Products by Stage and Mechanism of Action, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 50 Table 31: Number of Products by Stage and Route of Administration, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 51 Table 32: Number of Products by Stage and Molecule Type, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 53 Table 33: Number of Products by Stage and Target, Optic Neuritis 54 Table 34: Number of Products by Stage and Mechanism of Action, Optic Neuritis 56 Table 35: Number of Products by Stage and Route of Administration, Optic Neuritis 57 Table 36: Number of Products by Stage and Molecule Type, Optic Neuritis 59 Table 37: Optic Neuropathy - Pipeline by Amgen Inc, H2 2018 60 Table 38: Optic Neuropathy - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018 61 Table 39: Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, H2 2018 61 Table 40: Optic Neuropathy - Pipeline by Regenera Pharma Ltd, H2 2018 62 Table 41: Optic Neuropathy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018 62 Table 42: Glaucoma - Pipeline by AC Immune SA, H2 2018 63 Table 43: Glaucoma - Pipeline by Aerie Pharmaceuticals Inc, H2 2018 63 Table 44: Glaucoma - Pipeline by Allergan Plc, H2 2018 64 Table 45: Glaucoma - Pipeline by Altacor Ltd, H2 2018 64 Table 46: Glaucoma - Pipeline by Amarantus Bioscience Holdings Inc, H2 2018 65 Table 47: Glaucoma - Pipeline by Amgen Inc, H2 2018 65 Table 48: Glaucoma - Pipeline by Annexon Inc, H2 2018 66 Table 49: Glaucoma - Pipeline by Astellas Pharma Inc, H2 2018 66 Table 50: Glaucoma - Pipeline by Bial - Portela & Ca SA, H2 2018 67 Table 51: Glaucoma - Pipeline by BioAxone BioSciences Inc, H2 2018 67 Table 52: Glaucoma - Pipeline by Can-Fite BioPharma Ltd, H2 2018 68 Table 53: Glaucoma - Pipeline by Cellix Bio Pvt Ltd, H2 2018 68 Table 54: Glaucoma - Pipeline by Certa Therapeutics Pty Ltd, H2 2018 68 Table 55: Glaucoma - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018 69 Table 56: Glaucoma - Pipeline by D. Western Therapeutics Institute Inc, H2 2018 701.2 List of Figures Figure 1: Number of Products under Development for Optic Neuropathy 10 Figure 2: Number of Products under Development by Companies, Optic Neuropathy 11 Figure 3: Number of Products under Development for Glaucoma 13 Figure 4: Number of Products under Development by Companies, Glaucoma 14 Figure 5: Number of Products under Development by Universities/Institutes, Glaucoma 17 Figure 6: Number of Products under Development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 24 Figure 7: Number of Products under Development by Companies, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 25 Figure 8: Number of Products under Development for Optic Neuritis 28 Figure 9: Number of Products under Development by Companies, Optic Neuritis 29 Figure 10: Number of Products by Top 10 Targets, Optic Neuropathy 31 Figure 11: Number of Products by Stage and Top 10 Targets, Optic Neuropathy 31 Figure 12: Number of Products by Top 10 Mechanism of Actions, Optic Neuropathy 32 Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Optic Neuropathy 33 Figure 14: Number of Products by Routes of Administration, Optic Neuropathy 34 Figure 15: Number of Products by Stage and Routes of Administration, Optic Neuropathy 34 Figure 16: Number of Products by Molecule Types, Optic Neuropathy 35 Figure 17: Number of Products by Stage and Molecule Types, Optic Neuropathy 36 Figure 18: Number of Products by Top 10 Targets, Glaucoma 37 Figure 19: Number of Products by Stage and Top 10 Targets, Glaucoma 37 Figure 20: Number of Products by Top 10 Mechanism of Actions, Glaucoma 40 Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Glaucoma 41 Figure 22: Number of Products by Routes of Administration, Glaucoma 44 Figure 23: Number of Products by Stage and Routes of Administration, Glaucoma 45 Figure 24: Number of Products by Top 10 Molecule Types, Glaucoma 46 Figure 25: Number of Products by Stage and Top 10 Molecule Types, Glaucoma 46 Figure 26: Number of Products by Targets, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 47 Figure 27: Number of Products by Stage and Targets, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 48 Figure 28: Number of Products by Mechanism of Actions, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 49 Figure 29: Number of Products by Stage and Mechanism of Actions, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 49 Figure 30: Number of Products by Routes of Administration, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 50 Figure 31: Number of Products by Stage and Routes of Administration, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 51 Figure 32: Number of Products by Molecule Types, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 52 Figure 33: Number of Products by Stage and Molecule Types, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 52 Figure 34: Number of Products by Targets, Optic Neuritis 53 Figure 35: Number of Products by Stage and Targets, Optic Neuritis 54 Figure 36: Number of Products by Mechanism of Actions, Optic Neuritis 55 Figure 37: Number of Products by Stage and Mechanism of Actions, Optic Neuritis 55 Figure 38: Number of Products by Routes of Administration, Optic Neuritis 56 Figure 39: Number of Products by Stage and Routes of Administration, Optic Neuritis 57 Figure 40: Number of Products by Molecule Types, Optic Neuritis 58 Figure 41: Number of Products by Stage and Molecule Types, Optic Neuritis 58

Neuritis AC Immune SA Aerie Pharmaceuticals Inc Alkeus Pharmaceuticals Inc Allergan Plc Altacor Ltd Amarantus Bioscience Holdings Inc Annexon Inc Astellas Pharma Inc Bactevo Ltd Bial - Portela & Ca SA BioAxone BioSciences Inc Bionure Farma SL Biovista Inc Can-Fite BioPharma Ltd Cellix Bio Pvt Ltd Certa Therapeutics Pty Ltd Chong Kun Dang Pharmaceutical Corp coma Commence Bio Inc D. Western Therapeutics Institute Inc Disarm Therapeutics Inc Dompe Farmaceutici SpA Elsalys Biotech SA EyePoint Pharmaceuticals Inc Eyevensys SAS Fortify Therapeutics Inc Fortress Biotech Inc Gene Signal International SA GenSight Biologics SA Glaukos Corp Graybug Vision Inc Han Wha Pharma Co Ltd Handok Inc HitGen LTD ID Pharma Co Ltd InMed Pharmaceuticals Inc Inspyr Therapeutics Inc Ironwood Pharmaceuticals Inc Isarna Therapeutics GmbH Ixchel Pharma LLC Khondrion BV Kowa Co Ltd Kukje Pharmaceutical Industry Co Ltd Laboratorios SALVAT SA Laboratorios Sophia SA de CV Lee's Pharmaceutical Holdings Ltd Lipocure Ltd Meta-IQ ApS MimeTech Srl Mitobridge Inc Mitochon Pharmaceuticals Inc Mitotech SA Nemus Bioscience Inc Neurim Pharmaceuticals Ltd NicOx SA NoNO Inc Novaliq GmbH Novartis AG Ocular Therapeutix Inc Oculis ehf Ohr Pharmaceutical Inc Oncolys BioPharma Inc Pivot Pharmaceuticals Inc Profarma Q BioMed Inc Regenera Pharma Ltd ReNetX Bio Santen Pharmaceutical Co Ltd Santhera Pharmaceuticals Holding AG Senju Pharmaceutical Co Ltd Shire Plc Spark Therapeutics Inc Stealth BioTherapeutics Inc Sun Pharma Advanced Research Company Ltd Sylentis SAU Taejoon Pharm Co Ltd Teijin Pharma Ltd TikoMed AB Unity Biotechnology Inc